Psoriasis Clinical Trial

Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)

Summary

This study will be an open label study of secukinumab for the treatment of nail psoriasis. Secukinumab is an FDA-approved treatment for psoriasis. We will examine time to response and different methods of defining nail disease response.

View Full Description

Full Description

This study will be an open label study of secukinumab for the treatment of nail psoriasis. Secukinumab is an FDA-approved treatment for psoriasis. This is a single arm trial - all patients will receive the study drug. We will examine time to response and different methods of defining nail disease response.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Active psoriatic nail disease defined as a Minimum 4 or more fingernails OR NAPSI>20
Active skin psoriasis currently (no minimum PASI or BSA) or skin psoriasis in the past documented by a dermatologist
Age 18-85

Exclusion Criteria:

History of IL-17 inhibitor use (other therapies including TNF inhibitors or non- biologics DMARDS in the past are acceptable)
Inflammatory bowel disease
Metal implants or other concerns for use of MRI
Active infection
Patients may have a history of self-reported psoriatic arthritis but may not have active PsA at the time of screening.
We will exclude patients with onychomyosis of the fingernails on clippings

Study is for people with:

Psoriasis

Phase:

Phase 4

Estimated Enrollment:

40

Study ID:

NCT04535999

Recruitment Status:

Recruiting

Sponsor:

University of Pennsylvania

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Hospital at the University of Pennsylvania
Philadelphia Pennsylvania, 19104, United States More Info
Sarah Gillespie, MS
Contact
215-614-1840
[email protected]
Alexis Ogdie-Beatty, MD, MSCE
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Phase:

Phase 4

Estimated Enrollment:

40

Study ID:

NCT04535999

Recruitment Status:

Recruiting

Sponsor:


University of Pennsylvania

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.